EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

Editas Medicine, Inc. (EDIT) announced that it has entered into a collaboration and nonexclusive license agreement with Canada-based privately held company Genevant Sciences to develop in vivo gene editing medicines. Shares of Editas were up 2.4% in after-hours trading on Oct. 21, following the announcement of the news. The partnership aims to leverage Editas' CRISPR Cas12a genome editing systems with Genevant's proprietary lipid nanoparticle (LNP) technology to develop novel mRNA-LNP gene editing therapies ...